Supplementary Online Content


eFigure 1. Participant Flowchart for the Long-term Assessment of the ANRS HB03 VIHVAC-B Trial

eFigure 2. Duration of High Immune Response According to Vaccination Regimen

eTable. Details on How Missing Measurements of HBsAb Titers Were Imputed

This supplementary material has been provided by the authors to give readers additional information about their work.
**eFigure 1. Participant Flowchart for the Long-term Assessment of the ANRS HB03 VIHVAC-B Trial**

522 Adult patients with HIV-1 and CD4 counts ≥ 200 cells/mm³ screened for eligibility

- 85 Excluded
  - 48 Did not meet inclusion criteria
  - 27 Declined to participate
  - 6 Withdrew consent
  - 4 Lost to follow-up

437 Randomized

<table>
<thead>
<tr>
<th>Group</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>145 Randomized to receive 20-µg intramuscular x3 recombinant HBV vaccine (standard regimen)</td>
<td>141 Received vaccine, 4 Declined to participate</td>
</tr>
<tr>
<td>148 Randomized to receive 40-µg intramuscular x4 recombinant HBV vaccine</td>
<td>145 Received vaccine, 1 Declined to participate, 2 Did not meet inclusion criteria</td>
</tr>
<tr>
<td>144 Randomized to receive 4-µg intradermal x4 recombinant HBV vaccine</td>
<td>140 Received vaccine, 2 Declined to participate, 2 Did not meet inclusion criteria</td>
</tr>
</tbody>
</table>

At week 28, 141 included in primary analysis (4 Excluded, did not receive vaccine):
- 91 Responders
- 42 Non responders
- 8 No anti-HBs measurement

At week 28, 145 included in primary analysis (3 Excluded, did not receive vaccine):
- 119 Responders
- 10 Non responders
- 16 No anti-HBs measurement

At week 28, 140 included in primary analysis (4 Excluded, did not receive vaccine):
- 108 Responders
- 26 Non responders
- 6 No anti-HBs measurement

Anti-HBs titer measurement

**Responders at week 28**
- 85 at month 18
- 73 at month 30
- 61 at month 42

**Non responders at week 28**
- 11 at month 18
- 3 at month 30
- 1 at month 42

**No anti-HBs measurement at week 28**
- 2 at month 18
- 2 at month 30
- 1 at month 42

**Responders at week 28**
- 113 at month 18
- 100 at month 30
- 96 at month 42

**Non responders at week 28**
- 7 at month 18
- 3 at month 30
- 2 at month 42

**No anti-HBs measurement at week 28**
- 4 at month 18
- 4 at month 30
- 4 at month 42

**Responders at week 28**
- 94 at month 18
- 82 at month 30
- 70 at month 42

**Non responders at week 28**
- 16 at month 18
- 10 at month 30
- 6 at month 42

**No anti-HBs measurement at week 28**
- 0 at month 18
- 0 at month 30
- 0 at month 42

141 Included in secondary analyses (response at month 18, 30 and 42)
- 4 excluded (did not receive vaccine)
- 91 responders at week 28 included in secondary analysis (duration and kinetics of response at month 18, 30 and 42)

145 Included in secondary analyses (response at month 18, 30 and 42)
- 3 excluded (did not receive vaccine)
- 119 responders at week 28 included in secondary analysis (duration and kinetics of response at month 18, 30 and 42)

140 Included in secondary analyses (response at month 18, 30 and 42)
- 4 excluded, did not receive vaccine
- 108 responders at week 28 included in secondary analysis (duration and kinetics of response at month 18, 30 and 42)
eFigure 2. Duration of High Immune Response According to Vaccination Regimen (IM40X4, n=101; IM20X3, n=55; ID4X4, n=71).

No. at risk:
- 20-μg intramuscular × 3  57  28  22  19
- 40-μg intramuscular × 4 104  75  60  46
- 4-μg intradermal × 4  74  29  22  18

Generalized Log–rank: 40–μg intramuscular × 4 vs. 20–μg intramuscular × 3, P=.02
4–μg intradermal × 4 vs. 20–μg intramuscular × 3, P=.22
### eTable. Details on How Missing Measurements of HBsAb Titers Were Imputed

<table>
<thead>
<tr>
<th></th>
<th>IM20x3</th>
<th>IM40x4</th>
<th>ID4x4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>NR</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Week 28 status (I+2)</strong></td>
<td>91</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td><strong>Month 18</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sampled (A)</td>
<td>85</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>Excluded–sampled after a vaccination (B)</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Missing: Imputed as a non response (following a non response and no subsequent response) (C)</td>
<td>0</td>
<td>36</td>
<td>6</td>
</tr>
<tr>
<td>Used in complete cases analyses of response (A-B+C) (1)</td>
<td>81</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td>Missing: Imputed from multiple imputation (2)</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Month 30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sampled (A)</td>
<td>73</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Excluded–sampled after a vaccination (B)</td>
<td>6</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Missing: Imputed as a non response (following a non response and no subsequent response) (C)</td>
<td>9</td>
<td>42</td>
<td>6</td>
</tr>
<tr>
<td>Used in complete cases analyses of response (A-B+C) (1)</td>
<td>76</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td>Missing: Imputed from multiple imputation (2)</td>
<td>15</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Month 42</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sampled (A)</td>
<td>61</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Excluded–sampled after a vaccination (B)</td>
<td>7</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Missing: Imputed as a non response (following a non response and no subsequent response) (C)</td>
<td>18</td>
<td>42</td>
<td>7</td>
</tr>
<tr>
<td>Used in complete cases analyses of response (A-B+C) (1)</td>
<td>72</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td>Missing: Imputed from multiple imputation (2)</td>
<td>19</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HBsAB = hepatitis B surface antibodies; R= responders; NR= Non responders; NM= not measured.

© 2016 American Medical Association. All rights reserved.